Experience

Davis Polk advised the representatives of the underwriters in connection with an SEC-registered offering of $172.5 million aggregate principal amount of Encore Capital Europe Finance…

Davis Polk advised the joint book-running managers and representatives of the several underwriters and the lead manager in connection with a $50 million public offering of common…

Davis Polk advised the representatives of the several initial purchasers, in connection with the offering by National Life Insurance Company of $350 million of its 5.250% fixed-to-floating…

Davis Polk advised Sumitomo Mitsui Financial Group, Inc. on its SEC-registered takedown offering of senior TLAC notes, which consisted of $750 million aggregate principal amount of 3.748%…

Davis Polk represented NPB Neue Privat Bank AG (“NPB”) in connection with the only non-prosecution agreement for a Category 1 Swiss Bank under the U.S. Department of Justice’s (“DOJ”) Swiss…

Davis Polk advised the joint lead managers in connection with Mizuho Financial Group, Inc.’s debut SEC-registered takedown offering of Australian dollar-denominated senior notes, which…

Davis Polk represented NPB Neue Privat Bank AG (“NPB”) in connection with the only non-prosecution agreement for a Category 1 Swiss Bank under the U.S. Department of Justice’s (“DOJ”) Swiss…

Davis Polk advised the lead managers on an SEC-registered offering by TD Bank of (i) $1.6 billion aggregate principal amount of its 3.500% senior notes due 2023 and (ii) $400 million…

Davis Polk advised Auris Medical Holding AG on a public offering of common shares and warrants. The common shares are listed on the NASDAQ Global Market under the symbol “EARS.” Auris…

Davis Polk advised the joint book-running managers in connection with the $125 million public offering of common stock of CytomX Therapeutics, Inc. The shares are listed on the NASDAQ…